298 related articles for article (PubMed ID: 32237292)
1. Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.
Zhang Y; Wang Q; Reynolds GP; Yue W; Deng W; Yan H; Tan L; Wang C; Yang G; Lu T; Wang L; Zhang F; Yang J; Li K; Lv L; Tan Q; Li Y; Yu H; Zhang H; Ma X; Yang F; Li L; Chen Q; Wei W; Zhao L; Wang H; Li X; Guo W; Hu X; Tian Y; Ren H; Ma X; Coid J; Zhang D; Li T;
J Clin Psychiatry; 2020 Mar; 81(3):. PubMed ID: 32237292
[TBL] [Abstract][Full Text] [Related]
2. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
[TBL] [Abstract][Full Text] [Related]
3. Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
Vázquez-Bourgon J; Pérez-Iglesias R; Ortiz-García de la Foz V; Suárez Pinilla P; Díaz Martínez Á; Crespo-Facorro B
Psychopharmacology (Berl); 2018 Jan; 235(1):245-255. PubMed ID: 29075885
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
[TBL] [Abstract][Full Text] [Related]
5. High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.
Ono S; Sugai T; Suzuki Y; Yamazaki M; Shimoda K; Mori T; Ozeki Y; Matsuda H; Sugawara N; Yasui-Furukori N; Okamoto K; Sagae T; Someya T
BMC Psychiatry; 2018 Jun; 18(1):180. PubMed ID: 29879941
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.
Juncal-Ruiz M; Ramirez-Bonilla M; Gomez-Arnau J; Ortiz-Garcia de la Foz V; Suarez-Pinilla P; Martinez-Garcia O; Neergaard KD; Tabares-Seisdedos R; Crespo-Facorro B
Psychopharmacology (Berl); 2017 Sep; 234(17):2563-2570. PubMed ID: 28567698
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
Gómez-Revuelta M; Pelayo-Terán JM; Juncal-Ruiz M; Vázquez-Bourgon J; Suárez-Pinilla P; Romero-Jiménez R; Setién Suero E; Ayesa-Arriola R; Crespo-Facorro B
Int J Neuropsychopharmacol; 2020 Apr; 23(4):217-229. PubMed ID: 31974576
[TBL] [Abstract][Full Text] [Related]
8. A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.
Vázquez-Bourgon J; Ibáñez Alario M; Mayoral-van Son J; Gómez Revuelta M; Ayesa Arriola R; Juncal Ruiz M; Ortiz-García de la Foz V; Crespo Facorro B
Eur Neuropsychopharmacol; 2020 Oct; 39():46-55. PubMed ID: 32891516
[TBL] [Abstract][Full Text] [Related]
9. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.
Park Y; Hernandez-Diaz S; Bateman BT; Cohen JM; Desai RJ; Patorno E; Glynn RJ; Cohen LS; Mogun H; Huybrechts KF
Am J Psychiatry; 2018 Jun; 175(6):564-574. PubMed ID: 29730938
[TBL] [Abstract][Full Text] [Related]
10. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.
Newcomer JW; Ratner RE; Eriksson JW; Emsley R; Meulien D; Miller F; Leonova-Edlund J; Leong RW; Brecher M
J Clin Psychiatry; 2009 Apr; 70(4):487-99. PubMed ID: 19358783
[TBL] [Abstract][Full Text] [Related]
11. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Correll CU; Frederickson AM; Kane JM; Manu P
Schizophr Res; 2007 Jan; 89(1-3):91-100. PubMed ID: 17070017
[TBL] [Abstract][Full Text] [Related]
12. Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics.
Fjukstad KK; Engum A; Lydersen S; Dieset I; Steen NE; Andreassen OA; Spigset O
Eur Psychiatry; 2018 Feb; 48():71-78. PubMed ID: 29331603
[TBL] [Abstract][Full Text] [Related]
13. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
[TBL] [Abstract][Full Text] [Related]
14. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.
Newcomer JW; Meyer JM; Baker RA; Eudicone JM; Pikalov A; Vester-Blokland E; McQuade RD; Crandall DT; Carson WH; Marcus RN; L'italien G
Schizophr Res; 2008 Dec; 106(2-3):300-7. PubMed ID: 18973991
[TBL] [Abstract][Full Text] [Related]
15. The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study.
Chue P; Mandel FS; Therrien F
Curr Med Res Opin; 2014 Jun; 30(6):997-1005. PubMed ID: 24568177
[TBL] [Abstract][Full Text] [Related]
16. Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
Carbon M; Kapoor S; Sheridan E; Al-Jadiri A; Azzo S; Sarkaria T; Kane JM; Saito E; Correll CU
J Am Acad Child Adolesc Psychiatry; 2015 Sep; 54(9):718-727.e3. PubMed ID: 26299293
[TBL] [Abstract][Full Text] [Related]
17. The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia.
Zhang Y; Tao S; Coid J; Wei W; Wang Q; Yue W; Yan H; Tan L; Chen Q; Yang G; Lu T; Wang L; Zhang F; Yang J; Li K; Lv L; Tan Q; Zhang H; Ma X; Yang F; Li L; Wang C; Zhao L; Deng W; Guo W; Ma X; Zhang D; Li T
Curr Neuropharmacol; 2024; 22(1):159-167. PubMed ID: 36600620
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of electroacupuncture on metabolic syndrome due to olanzapine and risperidone: Study protocol for a randomized controlled pilot trial.
Ning Y; Jia H; Chen P; Zhu H; Yin D
Medicine (Baltimore); 2019 Sep; 98(38):e17237. PubMed ID: 31567988
[TBL] [Abstract][Full Text] [Related]
19. Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.
Ng-Mak D; Messali A; Huang A; Wang L; Loebel A
Am J Manag Care; 2019 Jul; 25(14 Suppl):S279-S286. PubMed ID: 31365818
[TBL] [Abstract][Full Text] [Related]
20. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
